TY - JOUR
T1 - The value of FDG-PET in the staging of gastric adenocarcinoma
T2 - A single institution retrospective review
AU - Serrano, Oscar K.
AU - Love, Charito
AU - Goldman, Inessa
AU - Huang, Kevin
AU - Ng, Nicole
AU - Abraham, Tony
AU - Da Silva, Raphaella
AU - Friedmann, Patricia
AU - Libutti, Steven K.
AU - Kennedy, Timothy J.
N1 - Publisher Copyright:
© 2016 Wiley Periodicals, Inc.
PY - 2016/5/1
Y1 - 2016/5/1
N2 - Background The value of FDG-PET in the staging of gastric adenocarcinoma (GA) has been subject to debate. Methods We performed a retrospective review of GA patients between 2006 and 2014 and identified those who had a CT and FDG-PET before initiating treatment. CT and FDG-PET images were analyzed by a blinded body radiologist and nuclear physician, respectively. Disease stage was assessed, looking at primary tumor (PT), locoregional (LLN) and distant lymph node disease (DLN), and metastasis (M). Results We identified 608 patients who had biopsy-proven GA and 207 (34.0%) had a CT and FDG-PET as part of their staging work-up. Of these, imaging from 166 (27.3%) patients was available for review. CT identified PT, LLN, DLN, and M in 120 (72.3%), 84 (50.6%), 25 (15.1%), and 32 (19.3%) patients, respectively; while FDG-PET identified PT, LLN, DLN, and M in 125 (75.3%), 78 (47.0%), 41 (24.7%), and 27 (16.3%) of patients, respectively. FDG-PET up-staged 31 (18.7%) patients while it down-staged 17 (10.2%) patients. Of patients who were up-staged, 20 (64.5%) developed progressive disease. Conclusions Our findings support the use of FDG-PET as a valuable adjunct to CT in the staging of GA, as it changed the stage in 48 (28.9%) patients. J. Surg. Oncol. 2016;113:640-646.
AB - Background The value of FDG-PET in the staging of gastric adenocarcinoma (GA) has been subject to debate. Methods We performed a retrospective review of GA patients between 2006 and 2014 and identified those who had a CT and FDG-PET before initiating treatment. CT and FDG-PET images were analyzed by a blinded body radiologist and nuclear physician, respectively. Disease stage was assessed, looking at primary tumor (PT), locoregional (LLN) and distant lymph node disease (DLN), and metastasis (M). Results We identified 608 patients who had biopsy-proven GA and 207 (34.0%) had a CT and FDG-PET as part of their staging work-up. Of these, imaging from 166 (27.3%) patients was available for review. CT identified PT, LLN, DLN, and M in 120 (72.3%), 84 (50.6%), 25 (15.1%), and 32 (19.3%) patients, respectively; while FDG-PET identified PT, LLN, DLN, and M in 125 (75.3%), 78 (47.0%), 41 (24.7%), and 27 (16.3%) of patients, respectively. FDG-PET up-staged 31 (18.7%) patients while it down-staged 17 (10.2%) patients. Of patients who were up-staged, 20 (64.5%) developed progressive disease. Conclusions Our findings support the use of FDG-PET as a valuable adjunct to CT in the staging of GA, as it changed the stage in 48 (28.9%) patients. J. Surg. Oncol. 2016;113:640-646.
KW - 2-deoxy-2-[(18)F]fluoro- d -glucose
KW - cancer
KW - positron emission tomography
KW - stomach
UR - http://www.scopus.com/inward/record.url?scp=84964443998&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84964443998&partnerID=8YFLogxK
U2 - 10.1002/jso.24190
DO - 10.1002/jso.24190
M3 - Review article
C2 - 27115836
AN - SCOPUS:84964443998
SN - 0022-4790
VL - 113
SP - 640
EP - 646
JO - Journal of Surgical Oncology
JF - Journal of Surgical Oncology
IS - 6
ER -
